Sg3 Management, LLC Zentalis Pharmaceuticals, Inc. Call Options Transaction History

Sg3 Management, LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$17.91 - $52.25 $297,306 - $867,350	-16,600 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$41.58 - $80.89 $690,228 - $1.34 Million	16,600 New	16,600 $766,000
Q4 2021 Feb 15, 2022	SELL	$66.92 - $84.79 $2.85 Million - $3.61 Million	-42,600 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$46.83 - $73.5 $1.99 Million - $3.13 Million	42,600 New	42,600 $2.84 Million

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $207M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.